182416-05-3

Basic information

• Product Name: 4-(2-Pyrimidinyl)-1-piperidinecarboxylic acid 1,1-dimethylethyl ester
• Synonyms: 4-(2-Pyrimidinyl)-1-piperidinecarboxylic acid 1,1-dimethylethyl ester;4-(2-Pyrimidinyl)-1-piperidinecarboxylic acid 1,1-dimethylethyl ester;tert-Butyl 4-(pyriMidin-2-yl)piperidine-1-carboxylate
• CAS NO: 182416-05-3
• Molecular Formula: C14H21N3O2
• Molecular Weight: 263.339
• Mol File: 182416-05-3.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 367.3±35.0 °C(Predicted)
• Appearance: /
• Density: 1.119±0.06 g/cm3(Predicted)
• PKA: 1.74±0.33(Predicted)
• CAS DataBase Reference: 4-(2-Pyrimidinyl)-1-piperidinecarboxylic acid 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-Pyrimidinyl)-1-piperidinecarboxylic acid 1,1-dimethylethyl ester(182416-05-3)
• EPA Substance Registry System: 4-(2-Pyrimidinyl)-1-piperidinecarboxylic acid 1,1-dimethylethyl ester(182416-05-3)

Safety Data

• Hazardous Substances Data: 182416-05-3(Hazardous Substances Data)

Usage

Description

4-(2-Pyrimidinyl)-1-piperidinecarboxylic acid 1,1-dimethylethyl ester, also known as rimonabant, is a chemical compound with potential pharmaceutical use. It is a CB1 cannabinoid receptor antagonist, which means it blocks the action of the CB1 receptor in the brain and peripheral tissues. This makes it a potential candidate for developing medications to treat obesity, metabolic disorders, and addiction.
Used in Pharmaceutical Industry:
4-(2-Pyrimidinyl)-1-piperidinecarboxylic acid 1,1-dimethylethyl ester is used as a CB1 cannabinoid receptor antagonist for its potential in treating obesity, metabolic disorders, and addiction. It has been studied for its effects on reducing food intake and body weight in clinical trials, as well as its potential in treating nicotine and drug addiction. However, due to concerns about its psychiatric side effects, including depression and anxiety, the development and commercialization of rimonabant have been discontinued in most countries.

Upstream product

• 375853-82-0 tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate 
• 4595-60-2 2-bromopyrimidine 
• 301673-14-3 tert-butyl 4-iodopiperidine-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 182416-02-0 4-hydroxy-4-pyrimidin-2-yl-piperidine-1-carboxylic acid tert-butyl ester 
• 182416-03-1 N-t-butoxycarbonyl-4-(2-pyrimidinyl)-1,2,3,6-tetrahydropyridine 

Downstream Products

• 151389-25-2 2-(paciperidin-4-yl)pyrimidine 
• 690261-64-4 2-(piperidin-4-yl)pyrimidine hydrochloride 

Relevant articles and documents

NOVEL COMPOUNDS

The invention relates to compounds of Formula (I) and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by mycobacterium, such as tuberculosis.

Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity

The present invention is directed to compounds of the formula I: Wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X, n and the broken lines are as defined herein which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.

New piperidinyl- and 1,2,3,6-tetrahydropyridinyl-pyrimidine derivatives as selective 5-HT1A receptor agonists with highly potent anti-ischemic effects

A series of new piperidinyl- and 1,2,3,6-tetrahydropyridinyl-pyrimidine derivatives were synthesized. Among these compounds, 4-methyl-2-(1,2,3,6- tetrahydropyridin-4-yl)pyrimidine derivative 23 (SUN N5147) exhibited sub-nanomolar affinity for 5-HT1A receptor with 1000-fold selectivity over both dopamine D2 and α1-adrenergic receptors and remarkable neuroprotective activity in a transient middle cerebral artery occlusion (t-MCAO) model.